Drug maker Eli Lilly and Company announced several leadership changes on Wednesday in a move to prepare the pharmaceutical firm for anticipated growth in the United States.

Patrik Jonsson, senior vice president and president of Lily Bio-Medicines was appointed senior vice president, president of Lilly USA and the company’s Chief Customer Officer, according to a company release. Ilya Yuffa, who current serves as vice president of US Diabetes, was named to replace Jonsson as senior vice president and president of Lilly Bio-Medicines.

“With a number of new medicines expected to launch in important therapeutic areas over the next several years, Lilly has a tremendous opportunity to serve many more patients in the US and provide industry-leading customer support,” David A. Ricks, chairman and CEO of Lilly, said in a statement. “Now is the time to name a dedicated executive to lead Lilly USA and our global customer-focused functions during a time of exciting growth. Patrik is an enterprise leader with a long track record of successfully managing Lilly businesses is complex markets around the world.”

Jonsson started his tenure at Lilly in 1990 as a sales representative in Sweden. Since joining the company, he has occupied several leadership positions across the Lilly’s international footprint, including general manager of Sweden, Scandinavia, Italy, and Japan. He became vice president and president of Lilly Bio-Medicines in 2019.

“Lilly Bio-Medicines is now home to a growing portfolio of new medicines and a pipeline of next generation molecules spanning immunology, pain, and neurodegeneration that will be critical to the future success of our company,” Ricks said. “Ilya’s effective leadership of our largest US franchise, US Diabetes, and his broad experience across many parts of our business have prepared him well to lead Lilly Bio-Medicines.”

Yuffa started serving as the leader of US Diabetes in 2018. Prior to that role, he was general manager of Italy.